133 related articles for article (PubMed ID: 28919989)
1. Cyclophosphamide treatment regulates the balance of functional/exhausted tumor-specific CD8
Hanoteau A; Henin C; Svec D; Bisilliat Donnet C; Denanglaire S; Colau D; Romero P; Leo O; Van den Eynde B; Moser M
Oncoimmunology; 2017; 6(8):e1318234. PubMed ID: 28919989
[TBL] [Abstract][Full Text] [Related]
2. Cyclophosphamide treatment induces rejection of established P815 mastocytoma by enhancing CD4 priming and intratumoral infiltration of P1E/H-2K(d) -specific CD8+ T cells.
Rahir G; Wathelet N; Hanoteau A; Henin C; Oldenhove G; Galuppo A; Lanaya H; Colau D; Mackay CR; Van den Eynde B; Moser M
Int J Cancer; 2014 Jun; 134(12):2841-52. PubMed ID: 24249003
[TBL] [Abstract][Full Text] [Related]
3. Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells.
Bae EA; Seo H; Kim BS; Choi J; Jeon I; Shin KS; Koh CH; Song B; Kim IK; Min BS; Han YD; Shin SJ; Kang CY
Cancer Res; 2018 Sep; 78(18):5315-5326. PubMed ID: 30012672
[TBL] [Abstract][Full Text] [Related]
4. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M
J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777
[TBL] [Abstract][Full Text] [Related]
5. Cyclophosphamide plus tumor necrosis factor-alpha chemoimmunotherapy cured mice: life-long immunity and rejection of re-implanted primary lymphoma.
Ehrke MJ; Verstovsek S; Krawczyk CM; Ujházy P; Zaleskis G; Maccubbin DL; Mihich E
Int J Cancer; 1995 Nov; 63(3):463-71. PubMed ID: 7591249
[TBL] [Abstract][Full Text] [Related]
6. Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8
Wu J; Waxman DJ
Oncoimmunology; 2015 Apr; 4(4):e1005521. PubMed ID: 26137402
[TBL] [Abstract][Full Text] [Related]
7. Thymic anti-tumor effectors in mice cured of lymphoma by cyclophosphamide plus TNF-alpha therapy: phenotypic and functional characterization up to 20 months after initial tumor inoculation.
Ehrke MJ; Verstovsek S; Pocchiari SK; Krawczyk CM; Ujházy P; Zaleskis G; Maccubbin DL; Meer JM; Mihich E
Int J Cancer; 1998 May; 76(4):579-86. PubMed ID: 9590137
[TBL] [Abstract][Full Text] [Related]
8. Demethylation of the PD-1 Promoter Is Imprinted during the Effector Phase of CD8 T Cell Exhaustion.
Ahn E; Youngblood B; Lee J; Lee J; Sarkar S; Ahmed R
J Virol; 2016 Oct; 90(19):8934-46. PubMed ID: 27466420
[TBL] [Abstract][Full Text] [Related]
9. CD8
Kurachi M
Semin Immunopathol; 2019 May; 41(3):327-337. PubMed ID: 30989321
[TBL] [Abstract][Full Text] [Related]
10. Functional restoration of exhausted CD4(+) and CD8(+) T cells in chronic viral infection by vinegar-processed flos of Daphne genkwa.
Uyangaa E; Choi JY; Patil AM; Kim JH; Kim SB; Kim K; Ryu HW; Oh SR; Eo SK
Comp Immunol Microbiol Infect Dis; 2015 Apr; 39():25-37. PubMed ID: 25744061
[TBL] [Abstract][Full Text] [Related]
11. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.
Kim K; Park S; Park SY; Kim G; Park SM; Cho JW; Kim DH; Park YM; Koh YW; Kim HR; Ha SJ; Lee I
Genome Med; 2020 Feb; 12(1):22. PubMed ID: 32111241
[TBL] [Abstract][Full Text] [Related]
12. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
13. The Transcription Factor TCF1 Preserves the Effector Function of Exhausted CD8 T Cells During Chronic Viral Infection.
Wang Y; Hu J; Li Y; Xiao M; Wang H; Tian Q; Li Z; Tang J; Hu L; Tan Y; Zhou X; He R; Wu Y; Ye L; Yin Z; Huang Q; Xu L
Front Immunol; 2019; 10():169. PubMed ID: 30814995
[TBL] [Abstract][Full Text] [Related]
14. High Levels of Eomes Promote Exhaustion of Anti-tumor CD8
Li J; He Y; Hao J; Ni L; Dong C
Front Immunol; 2018; 9():2981. PubMed ID: 30619337
[TBL] [Abstract][Full Text] [Related]
15. Increased Coexpression of PD-1, TIGIT, and KLRG-1 on Tumor-Reactive CD8
Hutten TJA; Norde WJ; Woestenenk R; Wang RC; Maas F; Kester M; Falkenburg JHF; Berglund S; Luznik L; Jansen JH; Schaap N; Dolstra H; Hobo W
Biol Blood Marrow Transplant; 2018 Apr; 24(4):666-677. PubMed ID: 29197680
[TBL] [Abstract][Full Text] [Related]
16. PD-1+ Tim3+ tumor-infiltrating CD8 T cells sustain the potential for IFN-γ production, but lose cytotoxic activity in ovarian cancer.
Sawada M; Goto K; Morimoto-Okazawa A; Haruna M; Yamamoto K; Yamamoto Y; Nakagawa S; Hiramatsu K; Matsuzaki S; Kobayashi E; Kawashima A; Hirata M; Iwahori K; Kimura T; Ueda Y; Kimura T; Wada H
Int Immunol; 2020 May; 32(6):397-405. PubMed ID: 32009163
[TBL] [Abstract][Full Text] [Related]
17. Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses.
Aregay A; Owusu Sekyere S; Deterding K; Port K; Dietz J; Berkowski C; Sarrazin C; Manns MP; Cornberg M; Wedemeyer H
J Hepatol; 2019 Nov; 71(5):889-899. PubMed ID: 31295532
[TBL] [Abstract][Full Text] [Related]
18. IFN-γ down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer.
Ding G; Shen T; Yan C; Zhang M; Wu Z; Cao L
BMC Cancer; 2019 Nov; 19(1):1053. PubMed ID: 31694582
[TBL] [Abstract][Full Text] [Related]
19. Premature terminal exhaustion of Friend virus-specific effector CD8+ T cells by rapid induction of multiple inhibitory receptors.
Takamura S; Tsuji-Kawahara S; Yagita H; Akiba H; Sakamoto M; Chikaishi T; Kato M; Miyazawa M
J Immunol; 2010 May; 184(9):4696-707. PubMed ID: 20351188
[TBL] [Abstract][Full Text] [Related]
20. Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines.
Liu J; Zhang S; Hu Y; Yang Z; Li J; Liu X; Deng L; Wang Y; Zhang X; Jiang T; Lu X
J Immunother; 2016 May; 39(4):171-80. PubMed ID: 27070448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
